U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H14ClN.8O2Si.ClH
Molecular Weight 712.824
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LORCASERIN HYDROCHLORIDE, ADSORBED ON SILICON DIOXIDE (1:2 W/W)

SMILES

Cl.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.C[C@H]1CNCCC2=C1C=C(Cl)C=C2

InChI

InChIKey=JDJKOSZGEYTQNN-UQDQVLRLSA-N
InChI=1S/C11H14ClN.ClH.8O2Si/c1-8-7-13-5-4-9-2-3-10(12)6-11(8)9;;8*1-3-2/h2-3,6,8,13H,4-5,7H2,1H3;1H;;;;;;;;/t8-;;;;;;;;;/m0........./s1

HIDE SMILES / InChI

Molecular Formula O2Si
Molecular Weight 60.0843
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C11H14ClN
Molecular Weight 195.689
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://www.eisai.com/news/news201464.html

Lorcaserin, currently marketed under the trade name Belviq and previously Lorqess during development, is a weight-loss drug developed by Arena Pharmaceuticals. Lorcaserin is a selective 5-HT2C receptor agonist, and in vitro testing of the drug showed reasonable selectivity for 5-HT2C over other related targets. 5-HT2C receptors are located almost exclusively in the brain, and can be found in the choroid plexus, cortex, hippocampus, cerebellum, amygdala, thalamus, and hypothalamus. The activation of 5-HT2C receptors in the hypothalamus is supposed to activate proopiomelanocortin (POMC) production and consequently promote weight loss through satiety. This hypothesis is supported by clinical trials and other studies. While it is generally thought that 5-HT2C receptors help to regulate appetite as well as mood, and endocrine secretion, the exact mechanism of appetite regulation is not yet known. Lorcaserin has shown 100x selectivity for 5-HT2C versus the closely related 5-HT2B receptor, and 17x selectivity over the 5-HT2A receptor

CNS Activity

Curator's Comment: Lorcaserin acts at 5-HT2C receptors in the central nervous system (CNS), particularly the hypothalamus, to reduce appetite

Originator

Curator's Comment: Discovered and developed by Arena Pharmaceuticals, Inc.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
15.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Belviq

Approved Use

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m^2 or greater (obese) or 27 kg/m^2 or greater (overweight) in the presence of at least one weight-related comorbid condition, (e.g., hypertension, dyslipidemia, type 2 diabetes)

Launch Date

1.34075515E12
PubMed

PubMed

TitleDatePubMed
Recent advancements in drug treatment of obesity.
2012 Oct
The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
2014 Apr
Nonincretin drugs in later-stage development.
2014 Jan
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
2014 Jun
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
2014 Mar 10
Patents

Sample Use Guides

One tablet of 10 mg twice daily
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Radioligand binding assays for human and rat 5-HT2A, 5-HT2B, and 5-HT2C receptors were developed using the 5-HT2 agonist [125I] DOI asadioligand.
Lorcaserin was evaluated for its ability to inhibit neurotransmitter uptake into rat brain synaptosomes. Lorcaserin weakly inhibited norepinephrine (EC50 = 2500 nM), serotonin (EC50 = 1400 nM), and dopamine (EC50 = 12,000 nM) uptake.
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:49:55 UTC 2023
Edited
by admin
on Sat Dec 16 11:49:55 UTC 2023
Record UNII
3423KE0K4Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LORCASERIN HYDROCHLORIDE, ADSORBED ON SILICON DIOXIDE (1:2 W/W)
Common Name English
LORCASERIN HYDROCHLORIDE PREMIX
Common Name English
Code System Code Type Description
PUBCHEM
122706894
Created by admin on Sat Dec 16 11:49:55 UTC 2023 , Edited by admin on Sat Dec 16 11:49:55 UTC 2023
PRIMARY
FDA UNII
3423KE0K4Y
Created by admin on Sat Dec 16 11:49:55 UTC 2023 , Edited by admin on Sat Dec 16 11:49:55 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY